Glucagon-like peptide-1

Gene expression

The proglucagon gene is expressed in several organs including the pancreas (α-cells of the islets of Langerhans), gut (intestinal enteroendocrine L-cells) and brain (caudal brainstem and hypothalamus). Pancreatic proglucagon gene expression is promoted upon fasting and hypoglycaemia induction and inhibited by insulin. Conversely, intestinal proglucagon gene expression is reduced during fasting and stimulated upon food consumption. In mammals, the transcription gives rise to identical mRNA in all three cell types, which is further translated to the 180 amino acid precursor called proglucagon. However, as a result of tissue-specific posttranslational processing mechanisms, different peptides are produced in the different cells.

In the pancreas (α-cells of the islets of Langerhans), proglucagon is cleaved by prohormone convertase (PC) 2 producing glicentin-related pancreatic peptide (GRPP), glucagon, intervening peptide-1 (IP-1) and major proglucagon fragment (MPGF).

In the gut and brain, proglucagon is catalysed by PC 1/3 giving rise to glicentin, which may be further processed to GRPP and oxyntomodulin, GLP-1, intervening peptide-2 (IP-2) and glucagon-like peptide-2 (GLP-2). Initially, GLP-1 was thought to correspond to proglucagon (72–108) suitable with the N-terminal of the MPGF, but sequencing experiments of endogenous GLP-1 revealed a structure corresponding to proglucagon (78–107) from which two discoveries were found. Firstly, the full-length GLP-1 (1–37) was found to be catalysed by endopeptidase to the biologically active GLP-1 (7–37). Secondly, the glycine corresponding to proglucagon (108) was found to serve as a substrate for amidation of the C-terminal arginine resulting in the equally potent GLP-1 (7–36) amide. In humans, almost all (80%) secreted GLP-1 is amidated, whereas a considerable part remains GLP-1 (7–37) in other species.

Secretion

GLP-1 is packaged in secretory granules and secreted into the hepatic portal system by the intestinal L-cells located primarily in the distal ileum and colon, but also found in the jejunum and duodenum. The L-cells are open-type triangular epithelial cells directly in contact with the lumen and neuro-vascular tissue and are accordingly stimulated by various nutrient, neural and endocrine factors.

GLP-1 is released in a biphasic pattern with an early phase after 10–15 minutes followed by a longer second phase after 30–60 minutes upon meal ingestion. As the majority of L-cells are located in the distal ileum and colon, the early phase is likely explained by neural signalling, gut peptides or neurotransmitters. Other evidence suggests the L-cells located in the proximal jejunum are sufficient to account for the early-phase secretion through direct contact with luminal nutrients. Less controversially, the second phase is likely caused by direct stimulation of L-cells by digested nutrients. The rate of gastric emptying is therefore an important aspect to consider, as it regulates the entry of nutrients into the small intestine where the direct stimulation occurs. One of the actions of GLP-1 is to inhibit gastric emptying, thus slowing down its own secretion (negative feedback) upon postprandial activation.

Fasting plasma concentrations of biologically active GLP-1 range between in humans and are increased 2- to 3-fold upon food consumption depending on meal size and nutrient composition. Individual nutrients, such as fatty acids, essential amino acids and dietary fibre have also been shown to stimulate GLP-1 secretion.

Sugars have been associated with various signalling pathways, which initiate depolarisation of the L-cell membrane causing an elevated concentration of cytosolic Ca2+, which in turn induces GLP-1 secretion. Fatty acids have been associated with the mobilisation of intracellular Ca2+ stores and subsequently release of Ca2+ into the cytosol. The mechanisms of protein-triggered GLP-1 secretion are less clear, but the amino acid proportion and composition appear important to the stimulatory effect.

Degradation

Once secreted, GLP-1 is extremely susceptible to the catalytic activity of the proteolytic enzyme dipeptidyl peptidase-4 (DPP-4). Specifically, DPP-4 cleaves the peptide bond between Ala8-Glu9 resulting in the abundant GLP-1 (9–36) amide constituting 60–80% of total GLP-1 in circulation. DPP-4 is widely expressed in multiple tissues and cell types and exists in both a membrane-anchored and soluble circulating form. Notably, DPP-4 is expressed on the surface of endothelial cells, including those located directly adjacent to GLP-1 secretion sites. Consequently, less than 25% of secreted GLP-1 is estimated to leave the gut intact. Additionally, presumably due to the high concentration of DPP-4 found on hepatocytes, 40–50% of the remaining active GLP-1 is degraded across the liver. Thus, due to the activity of DPP-4 only 10–15% of secreted GLP-1 reaches circulation intact.

Neutral endopeptidase 24.11 (NEP 24.11) is a membrane-bound zinc metallopeptidase widely expressed in several tissues, but found in particularly high concentrations in the kidneys, which is also identified accountable for the rapid degradation of GLP-1. It primarily cleaves peptides at the N-terminal side of aromatic or hydrophobic amino acids and is estimated to contribute by up to 50% to GLP-1 degradation. However, the activity only becomes apparent once the degradation of DPP-4 has been prevented, as the majority of GLP-1 reaching the kidneys has already been processed by DPP-4. Similarly, renal clearance appear more significant for the elimination of already inactivated GLP-1.

The resulting half-life of active GLP-1 is approximately 2 minutes, which is however sufficient to activate GLP-1 receptors.

Physiological functions

GLP-1 possesses several physiological properties making it (and its functional analogs) a subject of intensive investigation as a potential treatment of diabetes mellitus, as these actions induce long-term improvements along with the immediate effects. Although reduced GLP-1 secretion has previously been associated with attenuated incretin effect in patients with type 2 diabetes, further research indicates that GLP-1 secretion in patients with type 2 diabetes does not differ from healthy subjects.

The most noteworthy effect of GLP-1 is its ability to promote insulin secretion in a glucose-dependent manner. As GLP-1 binds to GLP-1 receptors expressed on pancreatic β cells, the receptors couple to G-protein subunits and activate adenylate cyclase, which increases the production of cAMP from ATP. Subsequently, activation of secondary pathways, including protein kinase A (PKA) and Epac2, alters cell ion channel activity, causing elevated levels of cytosolic Ca2+ that enhance exocytosis of insulin-containing granules. During the process, influx of glucose ensures sufficient ATP to sustain the stimulatory effect.

Additionally, GLP-1 ensures the β cell insulin stores are replenished to prevent exhaustion during secretion by promoting insulin gene transcription, mRNA stability and biosynthesis. GLP-1 also increases β cell mass by promoting proliferation and neogenesis while inhibiting apoptosis. As both type 1 and 2 diabetes are associated with reduction of functional β cells, this effect is desirable in diabetes treatment.

In the brain, GLP-1 receptor activation has been linked with neurotrophic effects including neurogenesis and neuroprotective effects including reduced necrotic and apoptotic signaling, cell death, and dysfunctions. In the diseased brain, GLP-1 receptor agonist treatment is associated with protection against a range of experimental disease models such as Parkinson's disease, Alzheimer's disease, stroke, traumatic brain injury, and multiple sclerosis. In accordance with the expression of GLP-1 receptor on brainstem and hypothalamus, GLP-1 has been shown to promote satiety and thereby reduce food and water intake. Consequently, diabetic subjects treated with GLP-1 receptor agonists often experience weight loss as opposed to the weight gain commonly induced with other treatment agents.

In the stomach, GLP-1 inhibits gastric emptying, acid secretion and motility, which collectively decrease appetite. By decelerating gastric emptying GLP-1 reduces postprandial glucose excursion which is another attractive property regarding diabetes treatment. However, these gastrointestinal activities are also the reason why subjects treated with GLP-1-based agents occasionally experience nausea.

GLP-1 has also shown signs of carrying out protective and regulatory effects in numerous other tissues, including heart, tongue, adipose, muscles, bones, kidneys, liver and lungs.

GLP-1 receptor agonists e.g., semaglutide, liraglutide commonly cause gastrointestinal adverse effects such as nausea, vomiting, diarrhea, constipation, and abdominal discomfort, especially during dose escalation, less common risks include pancreatitis, gallbladder disease, and hypoglycemia mainly with insulin sulfonylureas .

Research history

In the early 1980s, Richard Goodman and P. Kay Lund were postdoctoral researchers working in Joel Habener's laboratory at Massachusetts General Hospital. Starting in 1979, Goodman harvested DNA from American anglerfish islet cells and spliced the DNA into bacteria to find the gene for somatostatin; Lund then joined the Habener laboratory and used Goodman's bacteria to identify the gene for glucagon. In 1982, they published their discovery that the gene for proglucagon actually codes for three peptides, namely glucagon and two novel peptides. Those two novel peptides were later isolated, identified, and investigated by other researchers, and are now known as glucagon-like peptide-1 and glucagon-like peptide-2.

In the 1980s, worked on the identification of GLP-1 at Massachusetts General Hospital, where she was head of a peptide synthesis facility. To try to identify whether a specific fragment of GLP-q was an incretin, created an incretin-antibody and developed ways to track its presence. She identified that a stretch of 31 amino acids in the GLP-1 was an incretin. and her collaborators Daniel J. Drucker and Habener showed that small quantities of laboratory-synthesized GLP-1 could trigger insulin.

fought to have her name included in patents, with Mass General eventually agreeing to amend four patents to include her name. She received her one-third of drug royalties for one year.

The discovery of GLP-1's extremely short half-life meant that it was impossible to develop into a drug. This caused diabetes research to shift towards other therapeutic options such as targeting the GLP-1 receptor, which then led to the development of GLP-1 receptor agonists.

References

References

1. (June 2013). "Glucagon-like peptides 1 and 2 in health and disease: a review". [[Peptides (journal).
2. (May 2007). "Biology of incretins: GLP-1 and GIP". [[Gastroenterology (journal).
3. (October 2007). "The physiology of glucagon-like peptide 1". [[Physiological Reviews]].
4. (August 2009). "Immunoassays for the incretin hormones GIP and GLP-1". Best Practice & Research. Clinical Endocrinology & Metabolism.
5. (September 2014). "Glucagon-like peptide 1-potentiated insulin secretion and proliferation of pancreatic β-cells". [[Journal of Diabetes]].
6. (2004). "Circulation and degradation of GIP and GLP-1". [[Hormone and Metabolic Research]].
7. "Latest Medical News, Clinical Trials, Guidelines - Today on Medscape".
8. (August 2001). "Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes". [[The Journal of Clinical Endocrinology and Metabolism]].
9. (March 2004). "Intravenous glucagon-like peptide 1 normalizes blood glucose after major surgery in patients with type 2 diabetes". [[Critical Care Medicine]].
10. (October 2016). "Glucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic Successes". [[Pharmacological Reviews]].
11. (May 2013). "Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies". [[Diabetologia]].
12. (September 2013). "Glucagon-like peptide-1: modulator of β-cell dysfunction and death". [[Diabetes, Obesity & Metabolism]].
13. (October 2013). "Exendin-4 induced glucagon-like peptide-1 receptor activation reverses behavioral impairments of mild traumatic brain injury in mice". [[Age (journal).
14. (2008). "Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes". [[Diabetes & Metabolism]].
15. (April 2010). "GIP and GLP-1, the two incretin hormones: Similarities and differences". [[Journal of Diabetes Investigation]].
16. (December 2010). "Chronic treatment of exendin-4 affects cell proliferation and neuroblast differentiation in the adult mouse hippocampal dentate gyrus". [[Neuroscience Letters]].
17. (February 2008). "Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease". [[Journal of Neuroscience Research]].
18. (September 2014). "GLP-1 improves neuropathology after murine cold lesion brain trauma". [[Annals of Clinical and Translational Neurology]].
19. (December 2012). "Exendin-4 improved rat cortical neuron survival under oxygen/glucose deprivation through PKA pathway". [[Neuroscience (journal).
20. (February 2014). "Neuroprotective and anti-apoptotic effects of liraglutide on SH-SY5Y cells exposed to methylglyoxal stress". [[Journal of Neurochemistry]].
21. (September 2002). "Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4". [[The Journal of Pharmacology and Experimental Therapeutics]].
22. (April 2014). "Glucagon-like peptide-1 protects synaptic and learning functions from neuroinflammation in rodents.". [[Journal of Neuroscience Research]].
23. (January 2009). "GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism". [[Proceedings of the National Academy of Sciences of the United States of America]].
24. (November 2010). "Val8-glucagon-like peptide-1 protects against Aβ1-40-induced impairment of hippocampal late-phase long-term potentiation and spatial learning in rats". Neuroscience.
25. (June 2003). "Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron". [[Journal of Neuroscience Research]].
26. (2016). "Glucagon-Like Peptide-1 Analog, Liraglutide, Delays Onset of Experimental Autoimmune Encephalitis in Lewis Rats". [[Frontiers in Pharmacology]].
27. Ramírez-Mejía, Mariana M.. (2025). "GLP-1 receptor agonists and gallbladder disease risk: insights into molecular mechanisms and clinical implications". Therapeutic Advances in Endocrinology and Metabolism.
28. (September 30, 2023). "GLP-1 drugs are transforming diabetes, obesity and more. Could a Nobel be next?". [[STAT News]].
29. (2023-09-08). "Her work paved the way for blockbuster obesity drugs. Now, she's fighting for recognition".
30. (2024). "Foundational contributions of Svetlana Mojsov to the GLP-1 field". Exploration of Drug Science.
31. Mojsov, S.. (1992). "Structural requirements for biological activity of glucagon-like peptide-I". [[International Journal of Peptide and Protein Research]].
32. (September 1986). "Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing.". [[Journal of Biological Chemistry]].
33. (1987-02-01). "Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas.". [[Journal of Clinical Investigation]].
34. (May 1987). "Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line.". Proceedings of the National Academy of Sciences of the United States of America.
35. O'Rahilly, Stephen. (2021-04-15). "The islet's bridesmaid becomes the bride: Proglucagon-derived peptides deliver transformative therapies". [[Cell (journal).
36. (June 23, 2023). "Monster Diet Drugs Like Ozempic Started With Actual Monsters". [[The Wall Street Journal]].
37. (August 31, 2023). "Setauket scientist Andrew Young's work paves way for drugs like Ozempic". [[TBR News Media]].